Biotech News
GRI Bio Participates in a Virtual Investor CEO Connect Segment
Access the CEO Connect segment here
LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- <a...
Related news
GRIGRI Bio2026-08-24 14:05 EST
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
XGNExagen2026-07-28 13:00 EST
Exagen Inc. to Participate in Upcoming Investor Conference
STTKShattuck Labs2026-06-05 20:05 EST
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
KNSAKiniksa2026-05-29 20:01 EST
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
GRI Bio
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
Recent company news
GRIGRI Bio2026-08-24 14:05 EST
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRIGRI Bio2026-05-14 13:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-05-14 13:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-05-14 08:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Stock data
- Close
- 1.65 USD
- Market cap
- 3.56M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States